Gastrointestinal Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_3_2025 - Safety and Efficacy of Bevacizumab plus Concurrent Chemoradiotherapy for Recurrent or Metastatic Colorectal Cancer

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Safety and Efficacy of Bevacizumab plus Concurrent Chemoradiotherapy for Recurrent or Metastatic Colorectal Cancer
Y. Li, X. Zhu, X. Li, C. Shi, J. Geng, Y. Zhang, Y. Cai, and W. Wang; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Purpose/Objective(s): To investigate the safety and effect of treatment with bevacizumab (BEV) plus chemoradiotherapy (CRT) in patients with recurrent or metastatic colorectal cancer (CRC).

Materials/Methods: The study enrolled 37 patients with unresectable recurrent or metastatic CRC between January 2011 and April 2016. Patients received oral capecitabine 825 mg/m2/bid, 5 days per week, with or without oxaliplatin 130 mg/m2 every 3 weeks, along with BEV 5 mg/kg every 2 weeks. Radiotherapy was administered to 50-60Gy in 25-30 fractions. The log-rank test using the Kaplan-Meier method was performed to progression-free survival (PFS) and overall survival (OS).

Results: A total of 37 patients with recurrent or metastatic CRC were identified. The median age was 54 years (37-75). The median follow-up time was 39 months (14-62). The median number of cycles of oxaliplatin was 8 (1-49) and the median number of months of BEV was 2 (1-36). 97.3% (36/37) completed radiation therapy except for one due to hospital acquired pneumonia. 24.3% (9/37) of patients discontinued concurrent chemotherapy or BEV. The overall incidence of grade 3 to 4 adverse events during radiation treatment was 18.9% (leukopenia or neutropenia, 5 patients; fatigue, 1; diarrhea, 1). All received clinical evaluation one month after treatment. The overall response rate (ORR) and disease-control rate (DCR) was 35.1% and 86.5%, respectively. The median PFS and OS interval was 24 and 36 months, respectively. The 3-year and 5-year PFS rates were 37.1% and 24.1%, and the 3-year and 5-year OS rates were 43.3% and 31%, respectively.

Conclusion: The combination of CRT with BEV achieved acceptable outcomes without significantly increasing the toxicities, and it might be safe and feasible in patients with recurrent or metastatic CRC. More attention is needed in prospective randomized trials.

Author Disclosure: Y. Li: None. X. Zhu: None. J. Geng: None. Y. Zhang: None.

Send Email for Yongheng Li


Assets

SU_3_2025 - Safety and Efficacy of Bevacizumab plus Concurrent Chemoradiotherapy for Recurrent or Metastatic Colorectal Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Safety and Efficacy of Bevacizumab plus Concurrent Chemoradiotherapy for Recurrent or Metastatic Colorectal Cancer